Home Pharmaceuticals Contraceptive Drugs Market Size to Hit USD 37.94 Billion By 2033

Contraceptive Drugs Market Size, Share & Trends Analysis Report By Product (Oral Contraceptive Pills, Injectable Contraceptives, Topical Contraceptives), By Age Group (15–24 years, 25–34 years, 35–44 years, Above 44 years), By End-User (Homecare, Hospitals, Clinics) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Report Code: SRPH2112DR
Last Updated: May, 2025
Pages: 110
Author: Mitiksha Koul
Format: PDF, Excel

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Contraceptive Drugs Market Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Oral Contraceptive Pills
        1. By Value
      3. Injectable Contraceptives
        1. By Value
      4. Topical Contraceptives
        1. By Value
    3. By Age Group
      1. Introduction
        1. Age Group By Value
      2. 15–24 years
        1. By Value
      3. 25–34 years
        1. By Value
      4. 35–44 years
        1. By Value
      5. Above 44 years
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Homecare
        1. By Value
      3. Hospitals
        1. By Value
      4. Clinics
        1. By Value
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Oral Contraceptive Pills
        1. By Value
      3. Injectable Contraceptives
        1. By Value
      4. Topical Contraceptives
        1. By Value
    3. By Age Group
      1. Introduction
        1. Age Group By Value
      2. 15–24 years
        1. By Value
      3. 25–34 years
        1. By Value
      4. 35–44 years
        1. By Value
      5. Above 44 years
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Homecare
        1. By Value
      3. Hospitals
        1. By Value
      4. Clinics
        1. By Value
    5. U.S.
      1. By Product
        1. Introduction
          1. Product By Value
        2. Oral Contraceptive Pills
          1. By Value
        3. Injectable Contraceptives
          1. By Value
        4. Topical Contraceptives
          1. By Value
      2. By Age Group
        1. Introduction
          1. Age Group By Value
        2. 15–24 years
          1. By Value
        3. 25–34 years
          1. By Value
        4. 35–44 years
          1. By Value
        5. Above 44 years
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Homecare
          1. By Value
        3. Hospitals
          1. By Value
        4. Clinics
          1. By Value
    6. Canada
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Oral Contraceptive Pills
        1. By Value
      3. Injectable Contraceptives
        1. By Value
      4. Topical Contraceptives
        1. By Value
    3. By Age Group
      1. Introduction
        1. Age Group By Value
      2. 15–24 years
        1. By Value
      3. 25–34 years
        1. By Value
      4. 35–44 years
        1. By Value
      5. Above 44 years
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Homecare
        1. By Value
      3. Hospitals
        1. By Value
      4. Clinics
        1. By Value
    5. U.K.
      1. By Product
        1. Introduction
          1. Product By Value
        2. Oral Contraceptive Pills
          1. By Value
        3. Injectable Contraceptives
          1. By Value
        4. Topical Contraceptives
          1. By Value
      2. By Age Group
        1. Introduction
          1. Age Group By Value
        2. 15–24 years
          1. By Value
        3. 25–34 years
          1. By Value
        4. 35–44 years
          1. By Value
        5. Above 44 years
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Homecare
          1. By Value
        3. Hospitals
          1. By Value
        4. Clinics
          1. By Value
    6. Germany
    7. France
    8. Spain
    9. Italy
    10. Russia
    11. Nordic
    12. Benelux
    13. Rest of Europe
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Oral Contraceptive Pills
        1. By Value
      3. Injectable Contraceptives
        1. By Value
      4. Topical Contraceptives
        1. By Value
    3. By Age Group
      1. Introduction
        1. Age Group By Value
      2. 15–24 years
        1. By Value
      3. 25–34 years
        1. By Value
      4. 35–44 years
        1. By Value
      5. Above 44 years
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Homecare
        1. By Value
      3. Hospitals
        1. By Value
      4. Clinics
        1. By Value
    5. China
      1. By Product
        1. Introduction
          1. Product By Value
        2. Oral Contraceptive Pills
          1. By Value
        3. Injectable Contraceptives
          1. By Value
        4. Topical Contraceptives
          1. By Value
      2. By Age Group
        1. Introduction
          1. Age Group By Value
        2. 15–24 years
          1. By Value
        3. 25–34 years
          1. By Value
        4. 35–44 years
          1. By Value
        5. Above 44 years
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Homecare
          1. By Value
        3. Hospitals
          1. By Value
        4. Clinics
          1. By Value
    6. Korea
    7. Japan
    8. India
    9. Australia
    10. Taiwan
    11. South East Asia
    12. Rest of Asia-Pacific
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Oral Contraceptive Pills
        1. By Value
      3. Injectable Contraceptives
        1. By Value
      4. Topical Contraceptives
        1. By Value
    3. By Age Group
      1. Introduction
        1. Age Group By Value
      2. 15–24 years
        1. By Value
      3. 25–34 years
        1. By Value
      4. 35–44 years
        1. By Value
      5. Above 44 years
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Homecare
        1. By Value
      3. Hospitals
        1. By Value
      4. Clinics
        1. By Value
    5. UAE
      1. By Product
        1. Introduction
          1. Product By Value
        2. Oral Contraceptive Pills
          1. By Value
        3. Injectable Contraceptives
          1. By Value
        4. Topical Contraceptives
          1. By Value
      2. By Age Group
        1. Introduction
          1. Age Group By Value
        2. 15–24 years
          1. By Value
        3. 25–34 years
          1. By Value
        4. 35–44 years
          1. By Value
        5. Above 44 years
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Homecare
          1. By Value
        3. Hospitals
          1. By Value
        4. Clinics
          1. By Value
    6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. Rest of MEA
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Oral Contraceptive Pills
        1. By Value
      3. Injectable Contraceptives
        1. By Value
      4. Topical Contraceptives
        1. By Value
    3. By Age Group
      1. Introduction
        1. Age Group By Value
      2. 15–24 years
        1. By Value
      3. 25–34 years
        1. By Value
      4. 35–44 years
        1. By Value
      5. Above 44 years
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Homecare
        1. By Value
      3. Hospitals
        1. By Value
      4. Clinics
        1. By Value
    5. Brazil
      1. By Product
        1. Introduction
          1. Product By Value
        2. Oral Contraceptive Pills
          1. By Value
        3. Injectable Contraceptives
          1. By Value
        4. Topical Contraceptives
          1. By Value
      2. By Age Group
        1. Introduction
          1. Age Group By Value
        2. 15–24 years
          1. By Value
        3. 25–34 years
          1. By Value
        4. 35–44 years
          1. By Value
        5. Above 44 years
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Homecare
          1. By Value
        3. Hospitals
          1. By Value
        4. Clinics
          1. By Value
    6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest of LATAM
    1. Contraceptive Drugs Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Agile Therapeutics
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Allergan Plc
    3. Bayer AG
    4. GlaxoSmithKline Plc
    5. Johnson & Johnson
    6. Piramal Healthcare
    7. Pfizer Inc.
    8. Mylan N.V.
    9. Novartis AG
    10. Teva Pharmaceutical Industries Ltd
    11. Sanofi
    12. HLL Lifecare Ltd.
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer
Get This Report

Download Free Sample

Our Clients:

LG Electronics
AMCAD Engineering
KOBE STEEL LTD.
Hindustan National Glass & Industries Limited
Voith Group
International Paper
Hansol Paper
Whirlpool Corporation
Sony
Samsung Electronics
Qualcomm
Google
Fiserv
Veto-Pharma
Nippon Becton Dickinson
Merck
Argon Medical Devices
Abbott
Ajinomoto
Denon
Doosan
Meiji Seika Kaisha Ltd
LG Chemicals
LCY chemical group
Bayer
Airrane
BASF
Toyota Industries
Nissan Motors
Neenah
Mitsubishi
Hyundai Motor Company

We are featured on:

WhatsApp
Chat with us on WhatsApp
Address:
Office 515 A, Amanora Chambers,
Amanora Park Town, Hadapsar,
Pune 411028, Maharashtra, India.
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
DMCA.com Protection Status
Secure Payments:
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.